Viatris presents positive Phase 3 data for investigational low-dose contraceptive patch at ACOG

Viatris, Inc.

Viatris, Inc.

VTRS

0.00
  • Viatris flagged positive results from its previously announced Phase 3 trial of investigational low-dose estrogen combined hormonal contraceptive weekly patch MR-100A-01.
  • Data have not yet been delivered at meeting; six abstracts will be presented May 1-3, 2026 at ACOG Annual Clinical & Scientific Meeting in Washington, D.C.
  • Presentations are set to cover contraceptive efficacy and safety, with additional updates on adhesion performance and cycle control.
  • Viatris also plans to present pharmacokinetic comparisons versus oral contraceptive tablets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605010659PR_NEWS_USPR_____NE48648) on May 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.